555win cung cấp cho bạn một cách thuận tiện, an toàn và đáng tin cậy [thiết kế web xổ số]
Apr 11, 2024 · Xywav was originally FDA-approved in 2002 to treat excessive daytime sleepiness (EDS) and cataplexy (sudden muscle weakness triggered by strong emotions) in people at least 7 …
FDA-Approved Indications Xywav is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Nov 1, 2024 · Summary: At the 37th annual Psych Congress, Jazz Pharmaceuticals presented results from the phase 4 DUET trial on low-sodium Xywav, showing its effectiveness in treating …
Jun 16, 2025 · Xywav is also approved to treat excessive daytime sleepiness and cataplexy (sudden muscle weakness) related to narcolepsy. Side effects of Xywav when used to treat these …
Excessive daytime sleepiness Sleep inertia Severe grogginess or confusion when waking up regardless of how much sleep you get or how many alarms you set—feeling disoriented, irritable, …
Xywav (calcium, magnesium, potassium, and sodium oxybates): This is the first and only FDA-approved treatment specifically for idiopathic hypersomnia in adults. It is a lower-sodium oxybate …
XYWAV is the first and only FDA-approved medication to treat IH in adults. XYWAV has been studied across multiple symptoms of IH, such as excessive daytime sleepiness, sleep inertia, …
May 5, 2025 · Xywav is used for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy, and idiopathic hypersomnia (IH). Includes Xywav side effects, …
Jul 22, 2020 · Xywav is the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years Xywav …
Learn about the multiple symptoms of IH like excessive daytime sleepiness and sleep inertia. See full Prescribing Information & BOXED Warning about serious side effects, CNS depression, and …
Bài viết được đề xuất: